Bayer Announces Updated Analysis for Vitrakvi® (larotrectinib) Demonstrating High Response Rate and Duration of Response of Nearly Three Years in Adults and Children with TRK Fusion Cancer

WHIPPANY, N.J., Sept. 28, 2019 /PRNewswire/ -- Updated clinical data for Vitrakvi® (larotrectinib) in adult and pediatric patients with TRK fusion cancer demonstrated an overall response rate (ORR) of 79 percent (n=121; 95% CI, 72–85), including 16 percent complete responses (CR) and 63...

from PR Newswire: https://ift.tt/2mmlU61